Asymmetrically-substituted quadruplex-binding napththalene diimides showing potent activity in models for pancreatic cancer
Targeting quadruplexes in cancer genes and pathways by a novel class of asymmetrically-substituted napththalene diimides (SOP1812) with potent cellular and antitumour activity in models for pancreatic cancer. Overall design: Differential gene expression between treated and untreated MIA PaCa-2 cells after 6 h and 24 h treatment with a novel class of napththalene diimides (SOP1812), which were evaluated with RNA-seq.